Seattle Genetics, Inc. (SGEN)
(Delayed Data from NSDQ)
$67.25 USD
+0.33 (0.49%)
Updated May 3, 2019 04:00 PM ET
After-Market: $67.27 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$67.25 USD
+0.33 (0.49%)
Updated May 3, 2019 04:00 PM ET
After-Market: $67.27 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Company News For Oct 1, 2019
by Zacks Equity Research
Companies In The News Are: BX,THO,SGEN,XEL
Seattle Genetics' Enfortumab Vedotin BLA Gets Priority Review
by Zacks Equity Research
The FDA accepts Seattle Genetics (SGEN) and Astellas' BLA for enfortumab vedotin under a priority review to treat advanced/metastatic urothelial cancer. A verdict is pending on Mar 15, 2020.
Why Is Seattle Genetics (SGEN) Up 2.4% Since Last Earnings Report?
by Zacks Equity Research
Seattle Genetics (SGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Seattle Genetics (SGEN) Q2 Loss Narrows, Sales Top Estimates
by Zacks Equity Research
Seattle Genetics (SGEN) betters loss estimates and rides high on revenue beat in Q2.
Seattle Genetics (SGEN) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Seattle Genetics (SGEN) delivered earnings and revenue surprises of 38.46% and 14.25%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Seattle Genetics (SGEN) Q2 Earnings Expected to Decline
by Zacks Equity Research
Seattle Genetics (SGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Roche's Rozlytrek Gets Approval in Japan for Solid Tumors
by Zacks Equity Research
Roche's (RHHBY) oncology portfolio gets a boost with the approval of Rozlytrek for neurotrophic tyrosine receptor kinase fusion-positive, advanced recurrent solid tumors.
Roche's Polivy Gets FDA Nod, Gazyva Meets Goals in Phase II
by Zacks Equity Research
Roche's (RHHBY) hematology portfolio gets a boost as FDA approves Polivy for DLBCL, and lymphoma drug, Gazyva, meets goals in a phase II study.
Seattle Genetics, Astellas' Cancer Candidate Attains 44% ORR
by Zacks Equity Research
Seattle Genetics (SGEN) and Astellas post favorable data from the first cohort of a phase II study on enfortumab vedotin for treating advanced/metastatic urothelial cancer. Shares up as the candidate achieves 44% ORR.
Seattle Genetics (SGEN) Down 2.7% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Seattle Genetics (SGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Seattle Genetics (SGEN) Q1 Loss Narrows, Revenues Top Mark
by Zacks Equity Research
Seattle Genetics (SGEN) betters loss estimates in Q1 and also rides high on revenue beat.
Will Seattle Genetics (SGEN) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Seattle Genetics (SGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Seattle Genetics' Adcetris Progresses Well Amid Competition
by Zacks Equity Research
Seattle Genetics (SEGN) focuses on improving sales of its flagship product, Adcetris. The drug's label expansion programs also appear encouraging.
Seattle Genetics (SGEN) Surges: Stock Moves 7.6% Higher
by Zacks Equity Research
Seattle Genetics (SGEN) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.
Seattle Genetics Closes Enrollment in Cervical Cancer Study
by Zacks Equity Research
Seattle Genetics (SGEN) and partner Genmab end enrollment in the phase II study on tisotumab vedotin for treating patients with advanced/metastatic cervical cancer.
Seattle Genetics, Astellas Report Positive Cancer Study Data
by Zacks Equity Research
Seattle Genetics (SGEN) and partner Astellas present positive top-line data from the first cohort of a phase II study on enfortumab vedotin for treating patients with advanced/metastatic urothelial cancer.
Seattle Genetics (SGEN) Down 6.1% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Seattle Genetics (SGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Biotech Stock Roundup: Regeneron Impresses in Q4, Gilead Slumps, MacroGenics Soars
by Zacks Equity Research
Key highlights of the week were fourth-quarter results from Regeneron Pharmaceuticals and Ligand Pharmaceuticals along with other regulatory and pipeline updates.
Seattle Genetics' Adcetris Gets EC Nod for Label Expansion
by Zacks Equity Research
Seattle Genetics' (SGEN) partner, Takeda Pharmaceutical receives EC approval for Adcetris in combination with AVD to treat adults with previously untreated CD30+ stage IV cHL.
Seattle Genetics (SGEN) Q4 Loss Widens, Revenues Top Mark
by Zacks Equity Research
Seattle Genetics (SGEN) incurs wider-than-expected loss in Q4 but rides high on revenue beat.
Seattle Genetics (SGEN) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Seattle Genetics (SGEN) delivered earnings and revenue surprises of -46.15% and 5.26%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
What's in the Cards for Glaxo (GSK) This Earnings Season?
by Zacks Equity Research
Glaxo's (GSK) Vaccines segment is likely to witness strong sales in the fourth quarter.
Regeneron (REGN) to Report Q4 Earnings: Is a Beat in Store?
by Zacks Equity Research
Strong Eylea and Dupixent sales are likely to propel better-than-expected results for Regeneron (REGN) when it reports fourth-quarter results.
Seattle Genetics (SGEN) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
by Zacks Equity Research
Seattle Genetics (SGEN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Seattle Genetics (SGEN) Looks Good: Stock Adds 5.6% in Session
by Zacks Equity Research
Seattle Genetics (SGEN) saw a big move last session, as its shares jumped nearly 6% on Friday, amid huge volumes.